- $48.67m
- $129.31m
- $83.81m
bluebird delays filing of Q1 and 2023 reports, shares fall
Brief: Bluebird Bio Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For The First Quarter Of 2024
U.S. RESEARCH ROUNDUP-Acuity Brands, CSG Systems International, Nuvation Bio
U.S. STOCKS ON THE MOVE-Nuvation Bio, Seagate, AppFolio
U.S. STOCKS ON THE MOVE-Reddit, CONSOL Energy, Nuvation Bio
U.S. STOCKS ON THE MOVE-Gold miners , Alibaba, McCormick
Bluebird shares fall on downbeat Q4 revenue, plans to restate past financials
Brief: Bluebird Intends To Restate Financial Statements As Of And For Year Ended Dec 31, 2022 In Connection With Filing Of 2023 Form 10-K
Gene therapy maker bluebird to restate 2022 financials after accounting error (updated)
Gene therapy maker bluebird to restate 2022 financial statements
bluebird bio Inc expected to post a loss of 66 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-American Tower, Lennar, Nike
Brief: bluebird bio Secures Up To $175 Million Debt Financing With Hercules Capital
bluebird up on first outcomes-based Medicaid agreement for sickle cell gene therapy
Brief: Bluebird Bio Announces First Outcomes-Based Agreement With Medicaid For Sickle Cell Disease Gene Therapy
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Some US gene therapy developers set to end 2023 on a high
Newscasts - U.S. Day Ahead: Wall Street moves sideways as rate cut rally loses steam
U.S. STOCKS ON THE MOVE-Coinbase Global, Spirit AeroSystems, Crown Castle